A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
BO45217
Phase 3 other active
Quick answer
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer for KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) is a Phase 3 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Modality
- other
- Status
- active